{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-326916","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.337976+00:00","generated_at":"2026-05-16T12:36:45.119536+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inhibikase Therapeutics files prospectus supplement for $185M ATM offering via Jefferies","bullets":["Inhibikase may sell up to $185M of common stock under existing ATM program through Jefferies LLC.","Prospectus supplement filed Dec 19, 2025, under registration statement on Form S-3 (File 333-288213).","Sales Agreement with Jefferies LLC was originally dated June 20, 2025.","No specific use of proceeds stated; offering conducted from time to time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-326916","json":"https://secwatch.observer/filing/0001193125-25-326916.json","markdown":"https://secwatch.observer/filing/0001193125-25-326916.md","text":"https://secwatch.observer/filing/0001193125-25-326916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525326916/0001193125-25-326916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525326916/d212017d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:36:45.119536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}